108 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author최한곤-
dc.date.accessioned2019-01-17T10:44:03Z-
dc.date.available2019-01-17T10:44:03Z-
dc.date.issued2018-07-
dc.identifier.citationPHARMACEUTICAL RESEARCH, v. 35, No. 5, Article no. 96en_US
dc.identifier.issn1573-904X-
dc.identifier.issn0724-8741-
dc.identifier.urihttps://link.springer.com/article/10.1007/s11095-017-2337-6-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/81357-
dc.description.abstractPurpose Lung cancer is the leading cause of cancer-related deaths. The aim of this study was to design solid lipid core nanocapsules (SLCN) comprising a solid lipid core and a PEGylated polymeric corona for paclitaxel (PTX) and erlotinib (ERL) co-delivery to non-small cell lung cancer (NSCLC), and evaluate their physicochemical characteristics and in vitro activity in NCI-H23 cells. Methods PTX/ERL-SLCN were prepared by nanoprecipitation and sonication and physicochemically characterized by dynamic light scattering, transmission electron microscopy, differential scanning calorimetry, X-ray diffraction, and Fourier-transform infrared spectroscopy. In vitro release profiles at pH7.4 and pH5.0 were studied and analyzed. In vitro cytotoxicity and cellular uptake and apoptosis assays were performed in NCI-H23 cells. Results PTX/ERL-SLCN exhibited appropriately-sized spherical particles with a high payload. Both PTX and ERL showed pH-dependent and sustained release in vitro profiles. PTX/ERL-SLCN demonstrated concentration-and timedependent uptake by NCI-H23 cells and caused dosedependent cytotoxicity in the cells, which was remarkably greater than that of not only the free individual drugs but also the free drug cocktail. Moreover, well-defined early and late apoptosis were observed with clearly visible signs of apoptotic nuclei. Conclusion PTX/ERL-SLCN could be employed as an optimal approach for combination chemotherapy of NSCLC.en_US
dc.description.sponsorshipThis research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2015R1A2A2A01004118, 2015R1A2A2A04004806, and by the Medical Research Center Program (2015R1A5A2009124) through the NRF funded by MSIP).en_US
dc.language.isoen_USen_US
dc.publisherSPRINGER/PLENUM PUBLISHERSen_US
dc.subjectErlotiniben_US
dc.subjectpaclitaxelen_US
dc.subjectsolid lipid core nanocapsulesen_US
dc.subjectnon-small cell lung canceren_US
dc.subjectHIGH-DOSE CISPLATINen_US
dc.subjectCOMBINATION CHEMOTHERAPYen_US
dc.subjectPHASE-IIen_US
dc.subjectSEQUENTIAL DELIVERYen_US
dc.subjectDRUG-DELIVERYen_US
dc.subjectSINGLE-AGENTen_US
dc.subjectMITOMYCIN-Cen_US
dc.subjectNANOPARTICLESen_US
dc.subjectTHERAPYen_US
dc.subjectVINORELBINEen_US
dc.titlePaclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Canceren_US
dc.typeArticleen_US
dc.relation.no5-
dc.relation.volume35-
dc.identifier.doi10.1007/s11095-017-2337-6-
dc.relation.page1-11-
dc.relation.journalPHARMACEUTICAL RESEARCH-
dc.contributor.googleauthorGupta, Biki-
dc.contributor.googleauthorPoudel, Bijay Kumar-
dc.contributor.googleauthorRegmi, Shobha-
dc.contributor.googleauthorPathak, Shiva-
dc.contributor.googleauthorRuttala, Hima Bindu-
dc.contributor.googleauthorGautam, Milan-
dc.contributor.googleauthorAn, Gyeong Jin-
dc.contributor.googleauthorJeong, Jee-Heon-
dc.contributor.googleauthorChoi, Han-Gon-
dc.contributor.googleauthorYong, Chul Soon-
dc.contributor.googleauthorKim, Jong Oh-
dc.relation.code2018000596-
dc.sector.campusE-
dc.sector.daehakCOLLEGE OF PHARMACY[E]-
dc.sector.departmentDEPARTMENT OF PHARMACY-
dc.identifier.pidhangon-
Appears in Collections:
COLLEGE OF PHARMACY[E](약학대학) > PHARMACY(약학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE